The Drug and Therapeutics Bulletin (DTB) Podcast is your source for practical, independent, and evidence-based information on drugs, medication, and prescribing.
Join the Editor-in-Chief and Deputy Editor of DTB each month as they discuss the key highlights of the latest issue.
DTB - dtb.bmj.com - is published by BMJ Group, and offers rigorous, independent evaluations and practical advice on treatments and disease management for doctors, pharmacists, and healthcare professionals.
Subscribe to the DTB Podcast and get the latest drug and therapeutic insights.
* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
All content for DTB Podcast is the property of BMJ Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
The Drug and Therapeutics Bulletin (DTB) Podcast is your source for practical, independent, and evidence-based information on drugs, medication, and prescribing.
Join the Editor-in-Chief and Deputy Editor of DTB each month as they discuss the key highlights of the latest issue.
DTB - dtb.bmj.com - is published by BMJ Group, and offers rigorous, independent evaluations and practical advice on treatments and disease management for doctors, pharmacists, and healthcare professionals.
Subscribe to the DTB Podcast and get the latest drug and therapeutic insights.
* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
(Un)common sense in oncology, DOACs in device-detected AF, and hypertension in the elderly
DTB Podcast
19 minutes 49 seconds
1 year ago
(Un)common sense in oncology, DOACs in device-detected AF, and hypertension in the elderly
In this podcast recorded in early September, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the October issue of DTB. They discuss the editorial that highlights the work of the Common Sense in Oncology movement and its aim "to counteract the trend towards irrational, industry-designed, profit-driven cancer drug development" - https://dtb.bmj.com/content/62/10/146. They talk about the results of a systematic review and meta-analysis of two randomised controlled trials that assessed the effect of treating people who have device-detected subclinical atrial fibrillation (AF) with a direct oral anticoagulant - https://dtb.bmj.com/content/62/10/147. The main article discusses the management of hypertension in older people - https://dtb.bmj.com/content/62/10/149. They begin by highlighting an article* that considers the challenges associated with the introduction of new drugs for the treatment of Alzheimer's disease.
*Walsh S, Merrick R, Milne R, et al. Considering challenges for the new Alzheimer's drugs: clinical, population, and health system perspectives. Alzheimers Dement. 2024. doi: 10.1002/alz.14108. [Epub ahead of print 4 Aug 2024].https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14108
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.
DTB Podcast
The Drug and Therapeutics Bulletin (DTB) Podcast is your source for practical, independent, and evidence-based information on drugs, medication, and prescribing.
Join the Editor-in-Chief and Deputy Editor of DTB each month as they discuss the key highlights of the latest issue.
DTB - dtb.bmj.com - is published by BMJ Group, and offers rigorous, independent evaluations and practical advice on treatments and disease management for doctors, pharmacists, and healthcare professionals.
Subscribe to the DTB Podcast and get the latest drug and therapeutic insights.
* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
